Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS Post published:February 18, 2021 Post category:Press Release
Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds Post published:February 10, 2021 Post category:Press Release
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease Post published:January 26, 2021 Post category:Press Release
Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore Post published:January 13, 2021 Post category:Press Release
Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications Post published:January 11, 2021 Post category:Press Release
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities Post published:January 6, 2021 Post category:Press Release
Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin Post published:December 15, 2020 Post category:Press Release
Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham Post published:December 9, 2020 Post category:Press Release
Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham Post published:December 7, 2020 Post category:Press Release
Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets Post published:December 4, 2020 Post category:Press Release